March 8, 2016

Helix BioPharma Corp. Reports on Advancement of Its L-DOS47 Phase I/II Study in Poland (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Registration Office of Medicinal Products, Medical Devices and Biocides in Poland and the Bioethics Committee has approved an amendment to the Phase I/II study (“LDOS002”) defining the dose and dosing regimen for the Phase II study.